Cargando…
Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer
T-cell therapies, such as chimeric antigen receptor (CAR) T-cell, bispecific T-cell engager (BiTE) and tumor-infiltrating lymphocyte (TIL) therapies, fight cancer cells harboring specific tumor antigens. However, activation of the immune response by these therapies can lead to a systemic inflammator...
Autores principales: | Ganatra, Sarju, Dani, Sourbha S., Yang, Eric H., Zaha, Vlad G., Nohria, Anju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830211/ https://www.ncbi.nlm.nih.gov/pubmed/36636447 http://dx.doi.org/10.1016/j.jaccao.2022.07.014 |
Ejemplares similares
-
Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer
por: Lopez-Mattei, Juan C., et al.
Publicado: (2021) -
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer
por: Zhang, Lili, et al.
Publicado: (2021) -
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology Primer
por: Henriksen, Peter A., et al.
Publicado: (2023) -
Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity: JACC: CardioOncology Primer
por: Kok, Cindy Y., et al.
Publicado: (2021) -
Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology
por: Porter, Charles, et al.
Publicado: (2022)